??T Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Lymphoblastic Leukemia
- Non Hodgkin's Lymphoma
- Peripheral T Cell Lymphoma
- Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Biological: Autologous ??T cells Cells will be extracted by apheresis, followed by expanding and activating. The autologous ??T cells product will be adoptive transferred.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
This is a single-centre, non-randomised, open label, no control, prospective clinical trial. The study will include the following sequential phases: sign informed consent, ??T cells pre-culture, screening and registration to the trial, apheresis, ??T cells preparation, pre-treatment for lymphodeplet...
This is a single-centre, non-randomised, open label, no control, prospective clinical trial. The study will include the following sequential phases: sign informed consent, ??T cells pre-culture, screening and registration to the trial, apheresis, ??T cells preparation, pre-treatment for lymphodepleting chemotherapy (selectable plan), treatment and follow-up. The study will evaluate the safety and efficacy of the autologous ??T cells in patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphoblastic leukemia (CLL) and peripheral T cell lymphoma (PTCL) expect for ??T lymphoma.
Tracking Information
- NCT #
- NCT04028440
- Collaborators
- Beijing GD Initiative Cell Therapy Technology Co., Ltd.
- Chinese Academy of Medical Sciences
- Investigators
- Principal Investigator: Dehui Zou, Dr. Institute of Hematology & Blood Disease Hospital
Get Well Soon